InvestorsObserver
×
News Home

Should You Add Aileron Therapeutics Inc (ALRN) Stock to Your Portfolio Monday?

Monday, November 06, 2023 02:03 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Aileron Therapeutics Inc (ALRN) Stock to Your Portfolio Monday?

Aileron Therapeutics Inc (ALRN) is near the bottom in its sector according to InvestorsObserver. ALRN gets an overall rating of 6. That means it scores higher than 6% of stocks. Aileron Therapeutics Inc gets a 2 rank in the Healthcare sector. Healthcare is number 5 out of 11 sectors.

Overall Score - 6
ALRN has an Overall Score of 6. Find out what this means to you and get the rest of the rankings on ALRN!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Aileron Therapeutics Inc Stock Today?

Aileron Therapeutics Inc (ALRN) stock is up 25% while the S&P 500 has fallen -0.11% as of 1:59 PM on Monday, Nov 6. ALRN has gained $0.29 from the previous closing price of $1.16 on volume of 521,834 shares. Over the past year the S&P 500 is up 14.37% while ALRN has fallen -63.75%. ALRN lost -$2.85 per share the over the last 12 months. Click Here to get the full Stock Report for Aileron Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App